SCHEMBL7929429

SCHEMBL7929429

O=C1NCC12CCCN2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18626026 1.00
SCHEMBL23009701 0.86
SCHEMBL1557333 0.84 GRIN1 (0.35)
SCHEMBL23009428 0.83
SCHEMBL1555859 0.82 GRIN1 (0.32)
SCHEMBL21225285 0.80 FKBP5 (0.34)
SCHEMBL22975111 0.80 FKBP5 (0.34)
SCHEMBL21225657 0.80 FKBP5 (0.34)
SCHEMBL21225659 0.80 FKBP5 (0.34)
Hydrochloric Acid SCHEMBL15012202 0.80 GRIN1 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250186392-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY HONG KONG CO LTD (HK) 2025-06-12 US disclosed
US-20220273629-A1 METHODS OF TREATING DISORDERS ASSOCIATED WITH ELEVATED LEVELS OF ANTIBODIES THAT INTERACT WITH THE NMDA RECEPTOR TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) 2022-09-01 US disclosed
US-20210332061-A1 NMDA RECEPTOR MODULATORS AND USES THEREOF NAUREX, INC. 2021-10-28 US disclosed
US-20210169964-A1 METHODS OF TREATING ALZHEIMER'S DISEASE, HUNTINGTON'S DISEASE, AUTISM, AND OTHER DISORDERS INNOVIVA TRC HOLDINGS LLC 2021-06-10 US disclosed
US-10906913-B2 NMDA receptor modulators and uses thereof NORTHWESTERN UNIVERSITY (US) 2021-02-02 US disclosed
EP-3679931-A2 METHODS OF TREATING ALZHEIMER'S DISEASE, HUNTINGTON'S DISEASE, AUTISM, AND OTHER DISORDERS Northwestern University (US) 2020-07-15 EP disclosed
EP-3564256-A1 NMDA RECEPTOR MODULATORS Naurex Inc. (US) 2019-11-06 EP disclosed
US-10441571-B2 Spiro-lactam NMDA receptor modulators and uses thereof APTINYX INC. (US) 2019-10-15 US disclosed
US-20190135862-A1 NDMA RECEPTOR MODULATORS AND USES THEREOF INNOVIVA TRC HOLDINGS LLC 2019-05-09 US disclosed
US-10273239-B2 Spiro-lactam NMDA receptor modulators and uses thereof APTINYX INC. (US) 2019-04-30 US disclosed
WO-2014120786-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF NAUREX, INC. (US) 2014-08-07 WO disclosed
US-8673843-B2 NMDA receptors modulators and uses thereof NORTHWESTERN UNIVERSITY (US) 2014-03-18 US disclosed
WO-2013063120-A2 NMDA RECEPTOR MODULATORS AND USES THEREOF NORTHWESTERN UNIVERSITY (US) 2013-05-02 WO disclosed
US-20130053325-A1 Secondary Structure Stabilized NMDA Receptor Modulators and Uses Thereof INNOVIVA TRC HOLDINGS LLC 2013-02-28 US disclosed
US-20130053325-A1 Secondary Structure Stabilized NMDA Receptor Modulators and Uses Thereof INNOVIVA TRC HOLDINGS LLC 2013-02-28 US disclosed
US-20130035292-A1 NMDA Receptors Modulators and Uses Thereof INNOVIVA TRC HOLDINGS LLC 2013-02-07 US disclosed
US-20110306586-A1 NMDA Receptor Modulators and Uses Thereof NAUREX, INC. 2011-12-15 US disclosed
US-20110306586-A1 NMDA Receptor Modulators and Uses Thereof NAUREX, INC. 2011-12-15 US disclosed
WO-2011100585-A1 SECONDARY STRUCTURE STABILIZED NMDA RECEPTOR MODULATORS AND USES THEREOF MOSKAL JOSEPH (US) 2011-08-18 WO disclosed
WO-2010033757-A1 NMDA RECEPTOR MODULATORS AND USES THEREOF NAUREX, INC. (US) 2010-03-25 WO disclosed